Marika Rudler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marika Rudler has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Dominique Thabut
Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Hepatology Department, Paris, France; INSERM, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
32 shared publications- Dominique Thabut
Brain-Liver Pitié Salpêtrière (BLIPS) Study Group, APHP Sorbonne Université, Centre de Recherche Saint-Antoine, Maladies Métaboliques, Biliaires Et Fibro- Inflammatoire du Foie, INSERM UMR_S 938, Paris, France
16 shared publications Charlotte Bouzbib
AP-HP, Sorbonne Université, Liver Intensive Care Unit, Hepatogastroenterology Department, La Pitié-Salpêtrière Hospital, Paris, France; INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
10 shared publicationsPhilippe Sultanik
AP-HP, Sorbonne Université, Liver Intensive Care Unit, Hepatogastroenterology Department, La Pitié-Salpêtrière Hospital, Paris, France; INSERM UMR_S 938, Centre de recherche Saint-Antoine, Maladies métaboliques, biliaires et fibro-inflammatoire du foie, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
9 shared publicationsMaxime Mallet
Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Hepatology Department, Paris, France
8 shared publications- Nicolas Weiss
Sorbonne Université, AP-HP.Sorbonne Université, Hopital Pitié-Salpétrière, Paris, France
7 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70691
Pre‐ TIPS Liver and Spleen Volumetry Are Not Associated With Liver‐Related Outcomes After TIPS Placement for Refractory Ascites
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) improves survival in refractory ascites. A careful patient's selection is mandatory as TIPS can lead to complications. Liver volumetry is predictive of outcomes before hepatic surgery, but data on its role before TIPS placement are scarce. We aimed to evaluate whether liver and spleen volume measurements are associated with prognosis after TIPS placement in patients with ascites. Methods: We analysed data from three French centers, treated with TIPS between 2017 and February 2022. Inclusion criteria encompassed a TIPS placement for refractory or recurrent ascites and availability of cross‐sectional imaging. Exclusion criteria included non‐cirrhotic portal hypertension, other indications for TIPS, hepatocellular carcinoma beyond Milan criteria, and extrahepatic malignancy. Liver and spleen volumes were measured using pre‐TIPS CT or MRI scans. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoints were overt hepatic encephalopathy (HE), recurrence of ascites, acute variceal bleeding, and jaundice. Results: The 160 patients were included (median age 60 years, male gender 83.8%, alcohol‐related cirrhosis 58.8%, with active alcohol consumption in 25.6%, Child‐Pugh B cirrhosis in 81.2%, median MELD score was 12). The 1‐year TFS was 60.1%. Multivariate analysis identified serum creatinine (HR = 1.01 95% CI [1.00–1.01], p = 0.04), total bilirubin (HR = 1.02 95% CI [1.02–1.04], p = 0.004), and portal pressure gradient (HR = 1.09 95% CI [1.01–1.18], p = 0.03) as independent factors associated with TFS. Neither liver‐to‐spleen volume ratios (LSVR) ( p = 0.36) nor liver volume index ( p = 0.92) were significantly associated with death or LT. Overall, 38.1% of patients developed overt HE after TIPS, with lower platelet count (HR = 1.01 95% CI [1.00–1.01], p = 0.04) emerging as an independent predictor. No radiological characteristics were associated with the recurrence of ascites. Conclusions: In this multicenter study, liver and spleen volumes were not associated with transplant‐free survival or liver‐related outcomes in patients undergoing TIPS for ascites. These findings suggest that liver volumetry should not be a determining factor in patient selection for TIPS placement.
- 11 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70691
Open AccessPre‐ TIPS Liver and Spleen Volumetry Are Not Associated With Liver‐Related Outcomes After TIPS Placement for Refractory Ascites
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) improves survival in refractory ascites. A careful patient's selection is mandatory as TIPS can lead to complications. Liver volumetry is predictive of outcomes before hepatic surgery, but data on its role before TIPS placement are scarce. We aimed to evaluate whether liver and spleen volume measurements are associated with prognosis after TIPS placement in patients with ascites. Methods: We analysed data from three French centers, treated with TIPS between 2017 and February 2022. Inclusion criteria encompassed a TIPS placement for refractory or recurrent ascites and availability of cross‐sectional imaging. Exclusion criteria included non‐cirrhotic portal hypertension, other indications for TIPS, hepatocellular carcinoma beyond Milan criteria, and extrahepatic malignancy. Liver and spleen volumes were measured using pre‐TIPS CT or MRI scans. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoints were overt hepatic encephalopathy (HE), recurrence of ascites, acute variceal bleeding, and jaundice. Results: The 160 patients were included (median age 60 years, male gender 83.8%, alcohol‐related cirrhosis 58.8%, with active alcohol consumption in 25.6%, Child‐Pugh B cirrhosis in 81.2%, median MELD score was 12). The 1‐year TFS was 60.1%. Multivariate analysis identified serum creatinine (HR = 1.01 95% CI [1.00–1.01], p = 0.04), total bilirubin (HR = 1.02 95% CI [1.02–1.04], p = 0.004), and portal pressure gradient (HR = 1.09 95% CI [1.01–1.18], p = 0.03) as independent factors associated with TFS. Neither liver‐to‐spleen volume ratios (LSVR) ( p = 0.36) nor liver volume index ( p = 0.92) were significantly associated with death or LT. Overall, 38.1% of patients developed overt HE after TIPS, with lower platelet count (HR = 1.01 95% CI [1.00–1.01], p = 0.04) emerging as an independent predictor. No radiological characteristics were associated with the recurrence of ascites. Conclusions: In this multicenter study, liver and spleen volumes were not associated with transplant‐free survival or liver‐related outcomes in patients undergoing TIPS for ascites. These findings suggest that liver volumetry should not be a determining factor in patient selection for TIPS placement.
- Open Access
- 25 April 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (7) , 988-990
Interobserver agreement in the assessment of active bleeding at endoscopy in patients with cirrhosis and acute variceal bleeding
- 25 April 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (7) , 988-990
Open AccessInterobserver agreement in the assessment of active bleeding at endoscopy in patients with cirrhosis and acute variceal bleeding
- Open Access
- 11 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (3) , 101750
Corrigendum to ‘Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis’ (JHEP Reports 7 [2025] 101611)
- 11 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (3) , 101750
Open AccessCorrigendum to ‘Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis’ (JHEP Reports 7 [2025] 101611)
- Open Access
- 29 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (3) , 101701
Animal naming test at discharge is associated with hepatic encephalopathy after elective TIPS
- 29 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (3) , 101701
Open AccessAnimal naming test at discharge is associated with hepatic encephalopathy after elective TIPS
- Open Access
- 29 November 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1) , e70154
Should Elective TIPS be Placed in Non‐Abstinent Patients With Alcohol‐Related Cirrhosis?
- 29 November 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (1) , e70154
Open AccessShould Elective TIPS be Placed in Non‐Abstinent Patients With Alcohol‐Related Cirrhosis?
- Open Access
- 1 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12)
Pre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis
- 1 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (12)
Open AccessPre-emptive TIPS should be considered in high-risk patients with both acute variceal bleeding and severe alcohol-related hepatitis
- Open Access
- 11 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11)
Overt hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis
- 11 August 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11)
Open AccessOvert hepatic encephalopathy after elective and preemptive TIPS: Risk factors and prognosis
- Open Access
- 11 March 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (5) , 738-749
Multiple Concomitant Precipitating Factors of Hepatic Encephalopathy Are Associated With a Poor Prognosis in Patients With Cirrhosis Admitted to Intensive Care Unit
Introduction: Management of hepatic encephalopathy relies on the identification and control of precipitating factors (PF). The prognostic value of a PF is unknown, which we aimed to explore. Patients and Methods: Single‐center retrospective study of cirrhotic patients included in a prospective cohort admitted to an intensive care unit (ICU) between 2019 and 2022. Inclusion criteria: cirrhosis; overt hepatic encephalopathy; ammonemia ≥ 50 μmol/L. PF considered: gastrointestinal bleeding, infection, acute renal injury (AKI), hyponatremia, constipation, non‐adherence to ammonia‐lowering therapy, TIPS, drugs precipitating overt hepatic encephalopathy. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoint was recurrence of hepatic encephalopathy. Results: 179/497 patients were included (men 72%, age 59, cause of cirrhosis alcohol (ALD)/metALD/MASLD/other in 41/21/6/32%, Child–Pugh A/B/C in 1/18/81%, West Haven grade 2/3/4 in 63/15/22%, MELD score 23). Reasons for admission were: gastrointestinal bleeding (31%), acute encephalopathy (28%), worsening liver function/jaundice (25%), infection (8%), and AKI (8%). All patients (100%) had at least one PF of hepatic encephalopathy (infection [64%], AKI [63%], drugs [41%], bleeding [36%], hyponatremia [22%], TIPS [12%], and constipation [1%]), and 82% had multiple concomitant PF. In‐hospital mortality was 50%, and median TFS was 0.8 months. In multivariate analysis, factors associated with death or liver transplantation were the number of PF, MELD and Child–Pugh scores, ACLF, AKI and infection. Hepatic encephalopathy reoccurred in 42% (median delay of 30 months). Conclusion: All patients had precipitating factor of hepatic encephalopathy, 82% of them having multiple concomitant precipitating factors. Concomitant multiple precipitating factors were associated with death or liver transplantation. A systematic screening for all precipitating factors of hepatic encephalopathy should be proposed for cirrhotics admitted to intensive care unit.
- 11 March 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (5) , 738-749
Open AccessMultiple Concomitant Precipitating Factors of Hepatic Encephalopathy Are Associated With a Poor Prognosis in Patients With Cirrhosis Admitted to Intensive Care Unit
Introduction: Management of hepatic encephalopathy relies on the identification and control of precipitating factors (PF). The prognostic value of a PF is unknown, which we aimed to explore. Patients and Methods: Single‐center retrospective study of cirrhotic patients included in a prospective cohort admitted to an intensive care unit (ICU) between 2019 and 2022. Inclusion criteria: cirrhosis; overt hepatic encephalopathy; ammonemia ≥ 50 μmol/L. PF considered: gastrointestinal bleeding, infection, acute renal injury (AKI), hyponatremia, constipation, non‐adherence to ammonia‐lowering therapy, TIPS, drugs precipitating overt hepatic encephalopathy. The primary endpoint was 1‐year transplant‐free survival (TFS). Secondary endpoint was recurrence of hepatic encephalopathy. Results: 179/497 patients were included (men 72%, age 59, cause of cirrhosis alcohol (ALD)/metALD/MASLD/other in 41/21/6/32%, Child–Pugh A/B/C in 1/18/81%, West Haven grade 2/3/4 in 63/15/22%, MELD score 23). Reasons for admission were: gastrointestinal bleeding (31%), acute encephalopathy (28%), worsening liver function/jaundice (25%), infection (8%), and AKI (8%). All patients (100%) had at least one PF of hepatic encephalopathy (infection [64%], AKI [63%], drugs [41%], bleeding [36%], hyponatremia [22%], TIPS [12%], and constipation [1%]), and 82% had multiple concomitant PF. In‐hospital mortality was 50%, and median TFS was 0.8 months. In multivariate analysis, factors associated with death or liver transplantation were the number of PF, MELD and Child–Pugh scores, ACLF, AKI and infection. Hepatic encephalopathy reoccurred in 42% (median delay of 30 months). Conclusion: All patients had precipitating factor of hepatic encephalopathy, 82% of them having multiple concomitant precipitating factors. Concomitant multiple precipitating factors were associated with death or liver transplantation. A systematic screening for all precipitating factors of hepatic encephalopathy should be proposed for cirrhotics admitted to intensive care unit.
- 4 February 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (2) , 1-16
TIPS and hepatic encephalopathy in patients with cirrhosis
Despite a better understanding in its prognosis and pathogenesis, hepatic encephalopathy (HE) remains one of the major complications of Transjugular Intrahepatic Portosystemic Shunt (TIPS) with a prevalence ranging from 35 to 50%. Its epidemiology differs according to the indication for TIPS (salvage/rescue TIPS, preemptive (pTIPS) or elective TIPS). In salvage/rescue TIPS, the prognosis is linked to that of bleeding, and HE should not be a contraindication to TIPS, especially as bleeding is a common precipitating factor of HE. In pTIPS, i.e. TIPS performed within the 72 h after stabilization of acute variceal bleeding in high-risk patients, the risk rebleeding and HE is reduced, when compared to endoscopic and drugs treatment. As a consequence, the Baveno VII recommendations state that HE at admission should not be considered as a contraindication to pTIPS placement. In elective situations, such as refractory (intractable ascites (intolerance to diuretics) or resistant ascites (i.e. despite optimal diuretic treatment (spironolactone 400 mg/d and Furosemide 160 mg/d combined with low-salt treatment (< 5.2 g/day) or recurrent ascites (the need for at least 3 paracenteses per year) and secondary prophylaxis of variceal bleeding, it is recommended to systematically look for risk factors for HE, and chronic or refractory HE remain not recommended to TIPS in most centers. Chronic HE involves persistent neurological symptoms with fluctuating acute episodes. Recurrent HE refers to repeated episodes occurring within 6 months, while refractory HE is resistant to standard treatments, often requiring more aggressive management (Vilstrup et al. 2014). A careful selection of patients is mandatory before elective TIPS decision. Risk factors must be identified and corrected if possible before any TIPS decision is made. Management of HE after TIPS is based on identification of precipitating factors, curative treatment with lactulose as first-line therapy and rifaximin as second-line therapy, and nutritional management. In elective TIPS, prophylactic administration of rifaximin is recommended in order to decrease the risk of further HE development in selected patients (not in everyone, at least according to Baveno VII). Liver transplantation (LT) should be discussed with a multidisciplinary team as an alternative option to TIPS in case of high-risk of post-TIPS HE, and in case of refractory HE after TIPS.
- 4 February 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (2) , 1-16
TIPS and hepatic encephalopathy in patients with cirrhosis
Despite a better understanding in its prognosis and pathogenesis, hepatic encephalopathy (HE) remains one of the major complications of Transjugular Intrahepatic Portosystemic Shunt (TIPS) with a prevalence ranging from 35 to 50%. Its epidemiology differs according to the indication for TIPS (salvage/rescue TIPS, preemptive (pTIPS) or elective TIPS). In salvage/rescue TIPS, the prognosis is linked to that of bleeding, and HE should not be a contraindication to TIPS, especially as bleeding is a common precipitating factor of HE. In pTIPS, i.e. TIPS performed within the 72 h after stabilization of acute variceal bleeding in high-risk patients, the risk rebleeding and HE is reduced, when compared to endoscopic and drugs treatment. As a consequence, the Baveno VII recommendations state that HE at admission should not be considered as a contraindication to pTIPS placement. In elective situations, such as refractory (intractable ascites (intolerance to diuretics) or resistant ascites (i.e. despite optimal diuretic treatment (spironolactone 400 mg/d and Furosemide 160 mg/d combined with low-salt treatment (< 5.2 g/day) or recurrent ascites (the need for at least 3 paracenteses per year) and secondary prophylaxis of variceal bleeding, it is recommended to systematically look for risk factors for HE, and chronic or refractory HE remain not recommended to TIPS in most centers. Chronic HE involves persistent neurological symptoms with fluctuating acute episodes. Recurrent HE refers to repeated episodes occurring within 6 months, while refractory HE is resistant to standard treatments, often requiring more aggressive management (Vilstrup et al. 2014). A careful selection of patients is mandatory before elective TIPS decision. Risk factors must be identified and corrected if possible before any TIPS decision is made. Management of HE after TIPS is based on identification of precipitating factors, curative treatment with lactulose as first-line therapy and rifaximin as second-line therapy, and nutritional management. In elective TIPS, prophylactic administration of rifaximin is recommended in order to decrease the risk of further HE development in selected patients (not in everyone, at least according to Baveno VII). Liver transplantation (LT) should be discussed with a multidisciplinary team as an alternative option to TIPS in case of high-risk of post-TIPS HE, and in case of refractory HE after TIPS.
- 11 January 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , 767-768
Primary prophylaxis of acute variceal bleeding in patients with severe cirrhosis: Time for combination therapy?
- 11 January 2025
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (4) , 767-768
Primary prophylaxis of acute variceal bleeding in patients with severe cirrhosis: Time for combination therapy?